Claim and evidence Close ×
Isomorphic Labs announced on 7 January 2024 a strategic research collaboration with Novartis on small-molecule therapeutics against three undisclosed targets, stating an upfront payment of $37.5 million and eligibility for up to $1.2 billion in performance-based milestone payments. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Date 2024-01-07 · announcement Records dated 2024 → Activity stage announced Stage announced Amount exact · $37,500,000 Scope and limits Announced terms as Isomorphic Labs states them; the milestone figure is an "up to" eligibility, not a payment. The release also states Novartis funding of select research costs, unquantified. No research outcome is implied.
The evidence 03 primary source Supports the claim
Isomorphic Labs announces strategic multi-target research collaboration with Novartis ↗ Isomorphic Labs · 2024-01-07
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “small molecule therapeutics against three undisclosed targets” Location in source PDF p. 1, first paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Isomorphic Labs Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 e1c6975d8c71adee0d87242b349ac3c567adbb78902c747876e8156ffc748eac). PDF news release dated January 7, 2024, linked from the Isomorphic Labs article of that date; retrieved 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Isomorphic Labs, “Isomorphic Labs announces strategic multi-target research collaboration with Novartis”, 2024-01-07. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (7 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A20) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review. primary source Supports the claim
Isomorphic Labs announces strategic multi-target research collaboration with Novartis ↗ Isomorphic Labs · 2024-01-07
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs” Location in source PDF p. 1, terms paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Isomorphic Labs Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 e1c6975d8c71adee0d87242b349ac3c567adbb78902c747876e8156ffc748eac). PDF news release dated January 7, 2024, linked from the Isomorphic Labs article of that date; retrieved 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Isomorphic Labs, “Isomorphic Labs announces strategic multi-target research collaboration with Novartis”, 2024-01-07. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (17 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A20) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review. primary source Supports the claim
Isomorphic Labs announces strategic multi-target research collaboration with Novartis ↗ Isomorphic Labs · 2024-01-07
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “eligible to receive up to $1.2 billion in performance-based milestone” Location in source PDF pp. 1-2, terms paragraph
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Isomorphic Labs Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 e1c6975d8c71adee0d87242b349ac3c567adbb78902c747876e8156ffc748eac). PDF news release dated January 7, 2024, linked from the Isomorphic Labs article of that date; retrieved 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Isomorphic Labs, “Isomorphic Labs announces strategic multi-target research collaboration with Novartis”, 2024-01-07. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (10 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A20) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.
Date. Dated by the release.
Record ID aib-labs-iso-novartis-2024